Evidence map›Paper›PMID 42268523›Full record

Trial reportBreast cancer (Tokyo, Japan)2026

Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.

Tsuguo Iwatani, Norikazu Masuda, Shigehira Saji, Takuhiro Yamaguchi, Yasuyuki Kojima, Masahiro Kitada, Hiroshi Tada, Tsutomu Iwasa, Kei Koizumi, Hideo Shigematsu and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IIIEquivalence TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03264547 (A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03264547 phase3completednot on this map

A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)

TypeinterventionalSponsorJapan Breast Cancer Research GroupRan2017 to 2024Enrolled446ConditionsBreast CancerArmsPertuzumab, Trastuzumab, Docetaxel, Paclitaxel, Eribulin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tsuguo IwataniDepartment of Breast and Endocrine Surgery, St. Marianna University Hospital, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-7162-1515
Norikazu MasudaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-Ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp.ORCID http://orcid.org/0000-0002-7302-0278
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.ORCID http://orcid.org/0000-0002-6732-8030
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.ORCID http://orcid.org/0000-0002-7961-9417
Yasuyuki KojimaInstitute for Clinical Genetics and Genomics, Showa Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9991-0228
Masahiro KitadaDepartment of Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan.
Hiroshi TadaDepartment of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Tsutomu IwasaDepartment of Medical Oncology, Kindai University Hospital, Osaka, Japan.
Kei KoizumiDepartment of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Hideo ShigematsuDepartment of Breast Surgery, Hiroshima University Hospital, Hiroshima, Japan.ORCID http://orcid.org/0000-0001-9393-9655
Yasuaki SagaraDepartment of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-5705-1739
Toshitaka OkunoDepartment of Breast Surgery, Kobe City Nishi-Kobe Medical Center, Hyogo, Japan.
Yoshie HasegawaDepartment of Breast Surgery, Hachinohe City Hospital, Aomori, Japan.
Eriko TokunagaDepartment of Breast Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.ORCID http://orcid.org/0000-0002-1640-5315
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.ORCID http://orcid.org/0000-0003-3202-5512
Uhi TohDepartment of Breast Surgery, Kurume University Hospital, Fukuoka, Japan.ORCID http://orcid.org/0000-0002-1986-6643
Hiroki HasegawaMedical HQs, Eisai Co., Ltd., Tokyo, Japan.
Shun OsakaMedical HQs, Eisai Co., Ltd., Tokyo, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-4344-3317
Toshinari YamashitaDepartment of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-6479-1660

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough taxanes are a mainstay treatment for locally advanced or metastatic breast cancer (LABC/MBC), they often impair quality of life (QoL). Treatments that avoid taxane-related QoL deteriorations would be valuable.

methodsThe JBCRG-M06/EMERALD trial (NCT03264547, UMIN000027938) compared eribulin with a taxane, each combined with trastuzumab and pertuzumab, in patients with human epidermal growth factor receptor type 2 (HER2)-positive LABC/MBC. QoL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Module C30 (EORTC QLQ-C30) version 3.0. QoL deterioration was defined as a decrease in the Global Health Status (GHS) score by ≥ 10 points (minimum clinically important difference), disease progression, or death.

resultsQoL data were available for 210 (of 224 randomized) and 205 (of 222 randomized) patients in the eribulin and taxane groups, respectively. The median (95% confidence interval) time to QoL deterioration was 7.16 (6.28-8.34) months in the eribulin group versus 4.57 (4.17-6.14) months in the taxane group, with a hazard ratio of 0.80 (95% confidence interval 0.65-0.98; log-rank P = 0.08). QoL was maintained at 6 and 12 months in greater proportions of the eribulin group (62.7% and 30.5%) compared with the taxane group (43.5% and 25.5%). GHS scores remained stable over time in the eribulin group. GHS deteriorated between weeks 9 and 27 in the taxane group (i.e. during treatment) with subsequent recovery toward baseline.

conclusionsEribulin could help avoid the early deteriorations in QoL that occur during taxane therapy and maintain QoL for longer in patents with HER2-positive LABC/MBC receiving trastuzumab and pertuzumab.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFuransKetonesQuality of LifeAdultAgedAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsFemaleHumansMiddle AgedPolyether PolyketidesTaxoidsTrastuzumabAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonespertuzumabPolyether PolyketidestaxaneTaxoidsTrastuzumabEribulinHuman epidermal growth factor receptor 2 (HER2)Patient-reported outcomesQuality of lifeTaxanes

Identifiers

PMID42268523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.